About Biocartis
Biocartis is a company based in Mechelen (Belgium) founded in 2007. Biocartis has raised $305.3 million across 18 funding rounds from investors including Philips, Johnson & Johnson and KBC Bank & Verzekering. Biocartis has completed 1 acquisition, including Pronota. Biocartis offers products and services including Idylla Platform, Oncology Tests, and Research Assays. Biocartis operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
- Headquarter Mechelen, Belgium
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biocartis Nv
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biocartis
Biocartis offers a comprehensive portfolio of products and services, including Idylla Platform, Oncology Tests, and Research Assays.
Automated system for rapid molecular testing in oncology labs
Tests for detecting mutations in cancer biomarkers quickly
Assays for exploring new biomarkers in research settings
People of Biocartis
Unlock access to complete
Unlock access to complete
Leadership Team
7 people
Sales and Marketing
3 people
Product Management Team
3 people
Senior Team
3 people
Finance and Accounting
2 people
Legal and Compliance
2 people
Human Resources and Administration
2 people
Software Development Team
2 people
Unlock access to complete
Funding Insights of Biocartis
Biocartis has successfully raised a total of $305.3M across 18 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biocartis
Biocartis has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Philips, Johnson & Johnson and KBC Bank & Verzekering.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity is directed toward private and public companies.
|
Locked | Locked | Locked | |
|
Venture capital firm backed by Johnson & Johnson
|
Locked | Locked | Locked | |
|
Private debt funds are managed across multiple sectors.
|
Locked | Locked | Locked |
Investor details for Biocartis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biocartis
Biocartis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Pronota.
Investment portfolio details for Biocartis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Diagnostics for heart failure, pre-eclampsia, and sepsis are provided.
|
Locked | Locked | 2004 | Locked |
Complete acquisition details for Biocartis
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Biocartis
Detailed financials for Biocartis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biocartis Comparisons
Peer comparison for Biocartis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biocartis
Biocartis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Adhesive patch biopsies for skin cancer detection are provided.
|
Detailed competitors of Biocartis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biocartis
Complete news archive for Biocartis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biocartis
Biocartis was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Biocartis is headquartered in Mechelen, Belgium. It is registered at Mechelen, Antwerp, Belgium.
Biocartis is a funded company, having raised a total of $305.3M across 18 funding rounds to date.
Biocartis was founded in 2007 in Mechelen, Belgium, within the molecular diagnostics sector. Proprietary micro-technology platforms are utilized for integrated molecular and immunodiagnostics. Multiplexed detection, quantification, and amplification of bio-analytes such as proteins, nucleic acids, and small molecules are enabled. Analysis of biomolecules linked to disease risk factors, early detection, staging, treatment selection, and monitoring is supported across various applications.
Biocartis's top competitors include Guardant Health, Foundation Medicine and Natera.
Biocartis offers Idylla Platform, Oncology Tests, and Research Assays.
Biocartis has made 1 acquisition, including Pronota.
Biocartis has 19 investors. Key investors include Philips, Johnson & Johnson, KBC Bank & Verzekering, Debiopharm, and PMV.